Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Dr. Wang's merit review is aimed at providing a better understanding of the relationship between SLC6A3/SLC6A4 and the mental health of veterans exposed to high levels of combat stress, specifically focusing on PTSD symptoms, related co-morbidities, treatment outcomes and seeks new approaches to therapy for our Veteran population.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: VA Office of Research and Development
• Treatments: Paroxetine

Criteria

Inclusion Criteria:

1. Male and female combat veterans ages 18 years and older who meet DSM-III-R criteria for principle diagnosis of PTSD as determined by the CAP-S;

2. A minimum 6-month duration of PTSD illness; 3)CGI-S score of 4 or higher and a total CAPS-2 severity score of 50 or higher at the baseline visit;

3. Homozygous for either the S/S or L/L 5-HTT;

4. Females must not be pregnant or lactating and must agree to an acceptable form of contraception while receiving study medication and for 1 month after.

Exclusion Criteria:

1. Presence of any other primary axis I disorder (concurrent depression will be permitted if it is judged to be secondary to development for PTSD);

2. Suicide ideation or attempts within the past 3 months;

3. Alcohol or substance abuse or dependence in the past six months;

4. Evidence of clinically significant hepatic or renal disease;

5. Previous seizure disorder or condition predisposing to seizures, or on medications that might lower the seizure threshold

6. Any acute or unstable medical condition that might interfere with the safe conduct of the study;

7. Intolerance or hypersensitivity to citalopram or any other SSRI;

8. Treatment with a monoamine oxidase inhibitor within 14 days of initiating the study;

9. Concomitant treatment with serotonin agonists, other SSRIs, meperidine, tramadol or other medication as determined by the study clinician.

10. PTSD symptoms in need of immediate treatment as determined by clinical assessment from a psychiatrist not affiliated with the study.